Objective regression was achieved in patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and other types of B cell lymphoma via application of CAR T cells which are redirected against CD19 [8, 11, 12, 23]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.